Does the media prefer PRLD or ALVO?

In the previous week, Alvotech had 7 more articles in the media than Prelude Therapeutics. MarketBeat recorded 9 mentions for Alvotech and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.94 beat Alvotech's score of 0.84 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or SVRA more profitable?

Savara's return on equity of -87.19% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Savara N/A -87.19% -66.42%

Does the media favor PRLD or SVRA?

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 2 articles in the media. Prelude Therapeutics' average media sentiment score of 0.94 beat Savara's score of 0.48 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, EVO or PRLD?

Prelude Therapeutics has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 1.15 -$117.12M N/A N/A Prelude Therapeutics $12.14M 24.01 -$99.50M -$1.00 N/A

Does the media favor PRLD or CRON?

In the previous week, Cronos Group had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Cronos Group and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.94 beat Cronos Group's score of 0.63 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Prelude Therapeutics (PRLD) Competitors

$3.66 +0.16 (+4.57%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 0.00 (0.00%)

As of 07:01 PM Eastern

Compare

PRLD vs. ALVO, CVAC, SVRA, EVO, and CRON

Should you buy Prelude Therapeutics stock or one of its competitors? MarketBeat compares Prelude Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prelude Therapeutics include Alvotech (ALVO), CureVac (CVAC), Savara (SVRA), Evotec (EVO), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.

How does Prelude Therapeutics compare to Alvotech?

Prelude Therapeutics (NASDAQ:PRLD) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Prelude Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

In the previous week, Alvotech had 7 more articles in the media than Prelude Therapeutics. MarketBeat recorded 9 mentions for Alvotech and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.94 beat Alvotech's score of 0.84 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Alvotech	-14.36%	-11.92%	-7.58%

Alvotech has higher revenue and earnings than Prelude Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.01	-$99.50M	-$1.00	N/A
Alvotech	$586.32M	1.62	$27.92M	-$0.25	N/A

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 109.47%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 142.04%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

79.7% of Prelude Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Prelude Therapeutics beats Alvotech on 9 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to CureVac?

Prelude Therapeutics (NASDAQ:PRLD) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

CureVac has a net margin of 199.92% compared to Prelude Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
CureVac	199.92%	-23.03%	-19.09%

CureVac has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.01	-$99.50M	-$1.00	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Prelude Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Prelude Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 109.47%. CureVac has a consensus target price of $5.25, suggesting a potential upside of 12.66%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Prelude Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Prelude Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for CureVac. Prelude Therapeutics' average media sentiment score of 0.94 beat CureVac's score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Positive
CureVac	Neutral

Summary

Prelude Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Savara?

Prelude Therapeutics (NASDAQ:PRLD) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Prelude Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Savara has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prelude Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 109.47%. Savara has a consensus price target of $10.14, indicating a potential upside of 93.20%. Given Prelude Therapeutics' higher possible upside, equities analysts clearly believe Prelude Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 2 articles in the media. Prelude Therapeutics' average media sentiment score of 0.94 beat Savara's score of 0.48 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prelude Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.01	-$99.50M	-$1.00	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Savara's return on equity of -87.19% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Savara	N/A	-87.19%	-66.42%

Summary

Prelude Therapeutics beats Savara on 8 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Evotec presently has a consensus target price of $7.00, suggesting a potential upside of 142.21%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 109.47%. Given Evotec's stronger consensus rating and higher possible upside, research analysts plainly believe Evotec is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

5.8% of Evotec shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prelude Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.15	-$117.12M	N/A	N/A
Prelude Therapeutics	$12.14M	24.01	-$99.50M	-$1.00	N/A

Evotec has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

In the previous week, Prelude Therapeutics had 1 more articles in the media than Evotec. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Evotec. Evotec's average media sentiment score of 0.94 equaled Prelude Therapeutics'average media sentiment score.

Company	Overall Sentiment
Evotec	Positive
Prelude Therapeutics	Positive

Prelude Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Summary

Evotec and Prelude Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Prelude Therapeutics compare to Cronos Group?

Prelude Therapeutics (NASDAQ:PRLD) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Cronos Group had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Cronos Group and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.94 beat Cronos Group's score of 0.63 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Cronos Group has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Prelude Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Cronos Group	-1.14%	-1.26%	-1.20%

Prelude Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 109.47%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 15.13%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Prelude Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cronos Group has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.01	-$99.50M	-$1.00	N/A
Cronos Group	$146.59M	6.92	-$9.45M	$0.01	271.00

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Prelude Therapeutics beats Cronos Group on 9 of the 16 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$291.48M	$2.91B	$6.45B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-3.66	17.69	22.30	24.19
Price / Sales	24.01	739.65	581.44	138.36
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	3.36	3.85	9.84	6.72
Net Income	-$99.50M	$75.85M	$3.57B	$337.19M
7 Day Performance	-12.02%	-1.67%	-1.16%	0.48%
1 Month Performance	-22.13%	22.18%	3.85%	5.07%
1 Year Performance	291.32%	21.83%	27.40%	34.25%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	3.7294 of 5 stars	$3.66 +4.6%	$7.67 +109.5%	+285.8%	$291.48M	$12.14M	N/A	120
ALVO Alvotech	3.649 of 5 stars	$3.48 +4.2%	$7.60 +118.4%	-73.3%	$1.05B	$588.90M	N/A	1,460	News Coverage
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
SVRA Savara	2.1205 of 5 stars	$5.07 +1.0%	$9.13 +80.0%	+118.8%	$1.04B	N/A	N/A	20
EVO Evotec	3.0751 of 5 stars	$2.91 -4.0%	$7.00 +140.5%	-25.9%	$1.03B	$891.97M	N/A	4,553

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. ALVO, CVAC, SVRA, EVO, and CRON

How does Prelude Therapeutics compare to Alvotech?

Summary

How does Prelude Therapeutics compare to CureVac?

Summary

How does Prelude Therapeutics compare to Savara?

Summary

How does Prelude Therapeutics compare to Evotec?

Summary

How does Prelude Therapeutics compare to Cronos Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. ALVO, CVAC, SVRA, EVO, and CRON

How does Prelude Therapeutics compare to Alvotech?

Which has more risk and volatility, PRLD or ALVO?

Does the media prefer PRLD or ALVO?

Is PRLD or ALVO more profitable?

Which has preferable valuation and earnings, PRLD or ALVO?

Do analysts rate PRLD or ALVO?

Do institutionals and insiders have more ownership in PRLD or ALVO?

Summary

How does Prelude Therapeutics compare to CureVac?

Is PRLD or CVAC more profitable?

Which has stronger earnings & valuation, PRLD or CVAC?

Which has more volatility and risk, PRLD or CVAC?

Do insiders and institutionals have more ownership in PRLD or CVAC?

Do analysts rate PRLD or CVAC?

Does the media favor PRLD or CVAC?

Summary

How does Prelude Therapeutics compare to Savara?

Which has more volatility and risk, PRLD or SVRA?

Do insiders and institutionals believe in PRLD or SVRA?

Do analysts prefer PRLD or SVRA?

Does the media favor PRLD or SVRA?

Which has stronger valuation & earnings, PRLD or SVRA?

Is PRLD or SVRA more profitable?

Summary

How does Prelude Therapeutics compare to Evotec?

Do analysts recommend EVO or PRLD?

Do insiders & institutionals hold more shares of EVO or PRLD?

Which has preferable valuation and earnings, EVO or PRLD?

Which has more volatility and risk, EVO or PRLD?

Does the media refer more to EVO or PRLD?

Is EVO or PRLD more profitable?

Summary

How does Prelude Therapeutics compare to Cronos Group?

Does the media favor PRLD or CRON?

Which has more volatility & risk, PRLD or CRON?

Is PRLD or CRON more profitable?

Do analysts recommend PRLD or CRON?

Which has higher earnings & valuation, PRLD or CRON?

Do insiders and institutionals have more ownership in PRLD or CRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools